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Respiratory tract infections have an important clinical and economic impact and they are the
most common indication for antibiotic use in outpatient practice. This prospective, multicenter
non-controlled trial assessed the efficacy and safety of gatifloxacin in the treatment of community-
acquired respiratory tract infections. Patients were treated with a daily oral dose of gatifloxacin
400 mg for 7-14 days. The diagnosis of respiratory infection was made based on the clinical
condition and/or radiologic findings. A total of 5,044 adult patients with community-acquired
respiratory infections was treated with gatifloxacin in different centers in Brazil between March
1, 2001, and October 31, 2001. Among the 5,044 patients treated, 1,501 patients (29.76%) had
community-acquired pneumonia, 756 (14.99%) had acute exacerbation of chronic bronchitis and
2,787 (55.25%) had acute sinusitis. Of the total of patients treated, 3,607 (71.51%) were
considered cured, 1,261 (25%) progressed with some clinical improvement,  28 (0.56%)  presented
a relapse, 56 (1.11%) failed to treatment and 92 (1.82%) were unable to be evaluated. Adverse
events were described in  634 (12.57%) patients. The most common adverse events were: nausea
(2.24%); dyspepsia (1.86%); diarrhea (0.79%); change in taste (0.46%); insomnia and
irritability (0.22%); dizziness (0.77%); headache (0.42%); allergic reaction (0.18%); Central
Nervous System alterations – insomnia, agitation, anxiety – (0.46%). This study showed that the
treatment of respiratory tract infections with gatifloxacin was safe and efficient and had a low
incidence of adverse events.
Key Words: Gatifloxacin, community-acquired pneumonia, acute sinusitis, acute exacerbation
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Community-acquired respiratory tract infections are
responsible for the most part of morbidity and mortality
and represent a serious public health problem.
Community-acquired pneumonia remains an important
cause of hospitalization and death. It is estimated that
between 2 and 15/1,000 individuals become infected
with pneumonia each year and about 20% to 40% need
to be hospitalized; 5% to 30% of those patients need
to be treated in intensive care units [1-3]. In Brazil,
pneumonia is the first cause of death due to pulmonary
diseases with 40,000 deaths each year. Pneumonia is
also responsible for almost half a million hospitalizations
each year [2].
Treatment is often empirical and based on clinical
and radiologic diagnosis directed to the most common
organisms. An empiric regimen should take into account
the important role of Streptococcus pneumoniae and
Haemophilus influenzae, besides M. pneumoniae,
C. pneumoniae and L. pneumophila in community-
acquired bacterial pneumonias. It has recently been
reported an increase of pneumococci strains moderately
resistant to penicillin and more rarely some strains with
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a high level of resistance, a problem we now face in
Brazil but in a smaller degree than in the United States,
Asian and Latin American countries such as Mexico,
Argentina, Chile e Uruguay [4-6]. In a similar way, there
has been an increase in resistance of Haemophilus
influenzae and Staphylococcus aureus to a number of
antimicrobials [4]. Although a few domestic studies have
determined the etiology of community-acquired
pneumonia, Mycoplasma pneumoniae, Legionella spp.
and Chlamydia pneumoniae  are important organisms
involved in community-acquired pneumonia in many
countries [7,8]. Rocha, et al. (2000) evaluated 69 patients
with a diagnosis of community-acquired pneumonia who
were treated at a school hospital in São Paulo, Brazil,
between March 1995 and January 1997. Of that total,
34 (50%) had an etiologic diagnosis of atypical pneumonia,
with Clamydia spp. and Mycoplasma pneumoniae the
most frequent agents [23].
In patients with exacerbation of chronic bronchitis,
the attempts to isolate the etiologic agent are
unsuccessful due to the frequent previous
administration of antibiotics and because of bacterial
colonization of tracheobronchial tree in these patients.
Lower respiratory airways are almost always sterile
in healthy, non-smoker individuals. A number of
researches has shown that individuals with stable
chronic bronchitis can be colonized by bacteria that
are potentially pathogenic in the respiratory tree [9].
The main pathogens isolated from tracheobronchial
secretions, in these cases, are Haemophilus
influenzae, frequently the non-capsulated type,
Streptococcus pneumoniae and  Moraxella
catharralis with satisfactory accordance between the
expectorated samples and the specimens obtained
from the lower respiratory airways by means of
bronchoscopy or transtracheal aspiration [4,9]. Other
potentially pathogenic bacteria include aerobic Gram-
negative bacilli, but those are less common than H.
influenzae and pneumococcus.
Sinusitis are among the most frequent community-
acquired infections. The presence of mucopurulent
secretion and facial pain suggest the occurrence of
sinusitis, an inflammation of the lining of paranasal sinuses.
The majority of cases occurs as a complication of
respiratory viral infections or other infections of the upper
respiratory tract, and there are occasional cases caused
by the extension of a periodontal infection underneath
the maxillary sinus. The most frequent organism in acute
sinusitis is Streptococcus pneumoniae. Haemophilus
influenzae is more frequent in infants and children. The
role of group A streptococcus, staphylococcus and
Moraxella catarrhalis in acute sinusitis is a variable one.
In many studies about community-acquired maxillary
sinusitis in which the organisms were obtained from antral
puncture and adequately cultured, more than 50% of
bacteria isolated were Streptococcus pneumoniae or
non-capsulated H. influenzae [10].
New quinolones (gatifloxacin – TequinR;
levofloxacin – TavanicR/LevaquinR and moxifloxacin
– AvaloxR) have recently been launched for marketing
in Brazil. These new quinolones, particularly
gatifloxacin, a 8-metoxi fluorquinolone, show excellent
activity against pneumococcus, including penicillin-
resistant strains, as well as against H. influenzae and
M. catarrhalis [4,11]. Besides this activity,
gatifloxacin also presents good activity against Gram-
negative bacilli and atypical organisms which are
frequently involved in lower respiratory tract infections
[12]. Gatifloxacin is bactericidal and has excellent
pharmacokinetic properties. With an oral dose of 400
mg, peak serum concentration  (Cmax) reaches 3.7
mg/L after one to two  hours (Tmax) [12,13,17]. Its
bioavailability is 96%, it is about 20% bound to protein
and has a half-life of 8 hours [13,17]. As a result, it is
used only once a day which favors the patient’s
compliance to treatment. Elimination is mainly urinary.
Gatifloxacin has shown to be a safe medication with
a low incidence of adverse effects. Only 3% of patients
discontinue treatment because of adverse effects and
this is the lowest rate when compared with
levofloxacin, moxifloxacin and ciprofloxacin. The most
frequent side effects include nausea, headache,
dizziness and rarely diarrhea [12-14].
Many previous clinical trials with the objective of
evaluating the efficacy of antimicrobials for the
treatment of pneumonia are difficult to be assessed.
In this current study we evaluated the efficacy,
tolerability and safety of a new quinolone called
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gatifloxacin in the treatment of community-acquired
respiratory tract infections.
Materials and Methods
This prospective, open-label, noncomparative trial was
performed in 1,208 Brazilian medical centers and
comprised patients who were 18 years or older. The
objective was to evaluate the efficacy of gatifloxacin in the
treatment of community-acquired pneumonia, acute
rhinusinusitis and acute exacerbation of chronic bronchitis.
The following exclusion criteria were used: patient did not
consent to participate in the study, history of
hypersensitivity to quinolones, pregnancy and breast-
feeding, inability to use appropriate contraceptives during
the period of the study, patients with a history of chronic
asthma or cystic fibrosis, clinical diagnosis of viral
respiratory tract infection and malabsorption
syndromes or other gastrointestinal disorders which
may affect drug absorption.
Community-acquired pneumonia was defined as those
cases in which the patients presented rales or egophony
on pulmonary auscultation and at least two of the following
signs or symptoms: fever: (axillary temperature > 100.4oF);
chest pain; cough; purulent sputum; chills, malaise or
radiological findings consistent with pneumonia. Patients
with acute exacerbation of chronic bronchitis should
present two or more of the following signs and symptoms:
increase in sputum volume, purulent sputum, increase of
cough and dispnea. Sinusitis was diagnosed as the
presence of two or more of the following signs or symptoms:
facial pain/tenderness,  pain in sinuses or teeth, purulence
in nasal cavity, headache, fever (axillary temperature >
100.4oF), postnasal discharge. Treatment was performed
empirically and it did not require any material to be sent
for microbiological exam.
The posology used consisted of 400 mg once daily
for 7 to14 days for community-acquired pneumonia, 7
to 10 days for acute bacterial exacerbation of chronic
bronchitis and 10 days for acute sinusitis.
During the study, the patient was allowed to make
use of antihistamines, anti-inflammatory drugs,
bronchodilators and antipyretics.
Evaluation of efficacy and safety employed clinical
and laboratorial parameters. Clinical response to
therapeutics was evaluated according to the patient’s
evolution during the study. Clinical response was also
analyzed by the researcher responsible for each medical
center up to 48 hours after the end of treatment. Clinical
responses were classified as cure (complete absence
of all symptoms caused by the infection and no need of
additional antibiotic treatment), improvement (clear
reduction of symptoms of infection but there was an
incomplete disappearance of all symptoms; there was
no need to continue therapy), relapse (after an initial
improvement, there was a relapse of symptoms during
therapy and it was necessary to maintain antibiotic
treatment) and unable to determine (patient who lost
follow-up, did not conclude the cycle of evaluations or
was not evaluated due to other diseases). All adverse
events that occurred during treatment or up to 48 hours
after the end of the study were recorded.
Results
During the period between March 1, 2001, and
October 10, 2001, a total of 5,044 adult patients from
1,208 Brazilian hospitals and with community-acquired
respiratory infections were treated with gatifloxacin. Of
the 5,044 patients treated: 1,501 (29.76%) had
community-acquired pneumonia; 756 (14.99%) had
acute exacerbation of chronic bronchitis and 2,787
(55.25%) had acute sinusitis. Demographic data of the
patient population with respiratory tract infections are
shown in Table 1. There were 996 smokers among 5,018
patients (19.58%) and of the total of patients who had
acute exacerbation of chronic bronchitis who were not
smokers (n=526): 158 (30%) never smoked; 293
(55.7%) had smoked in the past and in 75 patients
(14.3%) this information was impossible to be obtained.
Most of the patients studied had a previous history
of respiratory tract infections: 1,807 (35.82%) patients
had sinusitis, 964 (19.11%) patients had bronchitis, 542
(10.75%) patients had pneumonia, 781 (15.48%)
patients had pharyngitis in the past. In the last 12 months
as of the beginning of treatment of the current infection
Respiratory Tract Infections With Gatifloxacin
152 BJID 2002; 6 (August)Respiratory Tract Infections With Gatifloxacin
Table 1. Characteristics of 5,044 patients with community-acquired respiratory infections treated with gatifloxacin
Variable Community-acquired Acute exacerbation Acute sinusitis
pneumonia of chronic bronchitis (n=2,787)
(n=1,501) crônica (n=756)
Gender:
Male 718 (47.9%) 403 (53.5%) 1,170 (42.1%)
Female 782 (52.1%) 350 (46.5%) 1,609 (57.9%)
Mean age (years) ± SD 49.15 ± 19.24 60.13 ± 15.69 37.92 ± 13.80
Mean weight (Kg)  ± SD 67.79 ± 12.32 66.81 ± 13.30 67.79 ± 12.84
Smocking [1,2]:
Yes 330 (22.1%) 226 (30.1%) 440 (15.9%)
No 1,166 (77.9%) 526 (69.9%) 2,330 (84.1%)
Information not available 5 (0.3%) 4 (0.5%) 17 (0.6%)
History of previous respiratory
tract infections:
Sinusitis 189 (12.6%) 94 (12.4%) 1,524 (54.7%)
Brochitis 231 (15.4%) 582 (77.0%) 151 (5.4%)
Pneumonia 270 (18.0%) 167 (22.1%) 105 (3.8%)
Pharyngitis 190 (12.7%) 59 (7.8%) 531 (19.1%)
Other 76 (5.1%) 30 (4.0%) 128 (4.6%)
Use of antibiotics in the
last three months:
Yes 447 (19.8%) 407 (53.8%) 1,017 (36.5%)
No 1,054 (70.2%) 349 (46.2%) 1,770 (63.5%)
Concomitant use of other
medications with gatifloxacin:
Steroid anti-inflamatory drug 155 (3.2%) 369 (48.8%) 914 (32.79%)
Non-steroid anti- 313 (20.85%) 51 (6.74%) 750 (26.91%)
   inflamatory drug
Antihistamine 67 (4.46%) 39 (5.16%) 471 (16.9%)
Bronchodilator 533 (35.5%) 623 (82.41%) 91 (3.26%)
Other 478 (31.84%) 156 (20.63%) 620 (22.25%)
[1] It was impossible to obtain information from all patients. [2] Of the total of patients with acute exacerbation of chronic
bronchitis who reported to be non-smokers (n=526): 158 (30%) never smoked; 293 (55.7%) had been smokers in the past and in
75 patients (14.3%) this information was impossible to be obtained.
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those patients had a mean  ± standard deviation: 1.6 ±
1.1 sinusitis episodes; 2.13 ± 2.64 episodes of
bronchitis; 1.29 ± 0.79 episodes of pneumonia and
1.64 ± 1.29 episodes of pharyngitis.
In terms of use of antimicrobials in the last three
months, 1,871 patients of a total of 5,044 (37.09%)
used some type of antimicrobial. The antimicrobials
most commonly used were: amoxicillin (40.94%);
macrolides (erythromycin and clarithromycin)
(19.99%); first and second-generation cephalosporins
(cephalexin, cefadroxil, cefaclor or cefuroxime)
(22.92%); ciprofloxacin (8.33%).
Concomitant use of medication was observed in
4,025 (79.80%) patients, and the drugs used included:
steroid anti-inflammatory drugs = 1,438 (35.73%)
patients, non-steroid anti-inflammatory drugs = 1,114
(27.68%) patients; antihistamine = 577 (14.34%)
patients, bronchodilators = 1,247 (30.98%) patients
and other medications in 1,254 (31.16%) patients.
Table 2 shows the efficacy and adverse events
related to treatment with gatifloxacin. The mean (±
standard deviation) duration of treatment was (in days)
9.91 ± 2.30, median of 10.
Of the total of patients treated, 3,607 (71.51%)
were considered cured, 1,261 (25%) progressed with
clinical improvement, 28 (0.56%) presented a relapse,
56 (1.11) failed to treatment and  92 (1.82%) were
unable to be evaluated.
Adverse events were described in 634 (12.57%)
patients. The most frequent adverse events were: nausea
(2.24%); dyspepsia (1.86%); diarrhea (0.79%);
change in taste (0.46%); insomnia and irritability
(0.22%); dizziness (0.77%); headache (0.42%); allergic
reaction (0.18%); alterations of Central Nervous
System – insomnia, agitation, anxiety – (0.46%).
Discussion
Most treatments for both upper and lower
respiratory tract infections are administered in an
empirical way. Consequently, antimicrobial treatment
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Tabela 2. Avaliação da eficácia e dos eventos adversos do tratamento com gatifloxacina
Variable Community-acquired Acute exacerbation Acute sinusitis
pneumonia of chronic bronchitis (n=2,787)
(n=1,501) crônica (n=756)
Total duration (days) of
gatifloxacin (400 mg/day) use:
Mean ± SD 10.09  ± 2.78 9.51  ± 2.61 9.93  ± 1.88
Median 10.0 10.0 10.0
Clinical reponse:
Cure 1,198 (79.8%) 350 (46.3%) 2,059 (73.9%)
Improvement 262 (17.5%) 375 (49.6%) 624 (22.4%)
Relapse 4 (0.3%) 7 (0.9%) 17 (0.6%)
Failure 14 (0.9%) 10 (1.3%) 32 (1.1%)
Not assessed 23 (1.5%) 14 (1.9%) 55 (2.0%)
Adverse events:
Present 128 (8.5%) 91 (12%) 415 (14.9%)
Absent 1,373 (91.5%) 665 (88.0%) 2,372 (85.1%)
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must take into account the microorganisms most
frequently related to the sites of infection and their
sensitivity to antimicrobials, their pharmacokinetic
characteristics, adverse effects and costs of the
therapeutic to be chosen [2,8].With the advent of new
antimicrobials of oral use with excellent efficacy against
many community-acquired infections, many patients can
be efficiently treated in the comfort of their homes.
However, the biggest challenge is to choose an efficient
therapy with less likelihood of inducing resistance.
The emergence of  bacteria that are resistant to
antibiotics is in general related to the excessive use of
certain antimicrobials in clinical practice, although this
relationship is not always confirmed by well-conducted
epidemiologic studies. Some bacterial strains have gene
complexes which are inter-correlated and as a
consequence, the use of an antibiotic can induce the
emergence of resistance to another similar compound.
Although the episode of resistance to a certain
antimicrobial is considered inevitable, the rational use
of those drugs can delay that kind of occurrence.
Therefore, for the treatment of a community-acquired
infection or an infection acquired in a hospital setting
we should use an antimicrobial with the least possibility
of developing resistance and with the highest activity
efficacy which can be determined by the
pharmacokinetic characteristics as well minimum
inhibitory concentration (MIC) that is enough to destroy
the organism causing that infection.
Respiratory tract infection is the most frequent cause
of antimicrobial use. Many of the respiratory infections
have a viral etiology and are caused mainly by influenza
virus, rhinovirus and adenovirus, and they do not need
to be treated with antimicrobials. The excessive use of
antimicrobials is directly related to the increase in
resistance among respiratory pathogens.
A study carried out by Sader, et al. (2001) which
evaluated the sensitivity [to antimicrobials] of bacteria
isolated from the respiratory tract of patients with
community-acquired infections in Brazil showed that
among S. pneumoniae (176 isolates), 71.6% were
sensitive to penicillin. High levels of resistance to penicillin
and cefotaxime were found in 2.3% and 4.0%,
respectively. The new quinolones – levofloxacin (MIC90;
2 mg/L) and gatifloxacin (MIC90; 0.5 mg/L) – were
active against 100% of the isolates tested. Among other
antimicrobials tested, the most active were (% of
sensitivity): chloramphenicol (97.5%) > clindamycin
(94%) > azithromycin (90.3%) > clarithromycin (89.4%)
> tetracycline (76.4%) > sulfamethoxazole/trimethoprim
(60.2%). The percentage of Haemophilus influenzae
(101 isolates) resistant to amoxicillin was 90.1%, while
only 9.0% of Moraxella catarrhalis (67 isolates) were
sensitive. Clavulanic acid restored amoxicillin’s activity
against H. influenzae and M. catarrhalis. However,
H. influenzae showed increased levels of resistance to
sulfamethoxazole/trimethoprim (55.1% sensitivity),
clarithromycin (80.4% sensitivity) and cefaclor (88.2%
sensitivity). All isolates of H. influenzae and M.
catarrhalis were sensitive to gatifloxacin (MIC90; < 0.06
mg/L for both) and showed very low MICs. The results
of this study reveal that the prevalence of S. pneumoniae
with a high level of resistance to penicillin is still low in
Brazil; however, the prevalence of S. pneumoniae with
intermediate resistance to penicillin and cross-reaction
with other categories of antibiotics, especially macrolides,
is relatively  high in our country. On the other hand, new
quinolones are highly active against S. pneumoniae and
other pathogens responsible for community-acquired
respiratory infections  and gatifloxacin showed a better
activity when compared to beta-lactamic antibiotics and
other quinolones [4].
A number of studies and consensus produced by
scientific societies have recommended the use of beta-
lactamic antibiotics (with or without beta-lactamase
inhibitor – such as amoxicillin associated with clavulanic
acid), macrolides (clarithromycin and azithromycin) and
fluorquinolones (levofloxacin, gatifloxacin and
moxifloxacin) [2,15,16] for the treatment of respiratory
infections. The definition of the best therapeutic regimen
in our country is difficult especially because of the
scarcity of studies that evaluate the etiology of
community-acquired pneumonias.
Gatifloxacin was used in clinical trials mainly in upper
and lower respiratory tract infections such as acute
exacerbation of chronic bronchitis (7 to 10 days),
community-acquired pneumonias (7 to 14 days),
atypical pneumonias (14 days) and acute sinusitis (10
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days) [14]. Gotfried et al (2001) evaluated the
appropriate duration of treatment in cases of acute
exacerbation of chronic bronchitis and they concluded
that a short duration of treatment with gatifloxacin (5
days) resulted in clinical cure and microbiological
eradication comparable to other treatments with a
duration of 7 or 10 days [22].
Another important aspect that should be pointed out
with the use of gatifloxacin is the possibility of sequential
treatment (intravenous to oral) mainly in serious infections
which require hospitalization. Dresser, et al. (2001)
compared the use of single therapy with gatifloxacin (98
patients) versus ceftriaxone in association or not with a
macrolide (105 patients) in the treatment of community-
acquired pneumonia who required hospitalization.
Sequential treatment was performed in 98% of patients
in each group. Clinical cure and microbiological
eradication were not statistically different among groups
and those results were 98% and 97% with gatifloxacin
versus 92% and 92% with ceftriaxone, respectively. The
mean cost was US$1,760.00 for patients treated with
gatifloxacin and US$2,125.00 for those treated with
ceftriaxone (p = 0,011) [21].
In our study we had some problems related to
structuring. Although we had the largest number of cases
in the country for evaluating the treatment of respiratory
tract infections and despite being a prospective and
multicenter study, it  was an open-label and
noncomparative trial. Clinical response (cure or
improvement) to treatment was excellent (96.5%). In
patients with pneumonia, which is considered a potentially
serious infection, cure was achieved in 79.8% and clinical
improvement was observed in 17.5%. A similar study
performed in Mexico by  Casillas, et al. (2000) comprised
17,923 patients with community-acquired respiratory
infections and showed cure or clinical improvement in
96.3% of patients treated with gatifloxacin. The most
common adverse effects were nausea (2.76%) and
headache (2.2%) [14].
In 756 patients treated for acute exacerbation of
chronic bronchitis, cure or clinical improvement was
observed in 725 individuals (95.9%). Among those treated
for acute sinusitis, cure or clinical improvement was
observed in 2,683 patients (96.3%). These findings are
similar to the ones in the study performed by Casillas, et
al. (2000) [14].
The efficacy of gatifloxacin was also shown in other
studies. Gatifloxacin administered once a day was just
as effective as clarithromycin 500 mg administered  twice
daily or levofloxacin in patients with community-acquired
pneumonia and it was more effective than  cefuroxime
axetil 250 mg administered twice a day in patients with
acute exacerbation of chronic bronchitis [18-20].
Adverse events were not frequent; they occurred
in 634 (12.57%) patients. The most common adverse
events were: nausea (2.24%); dyspepsia (1.86%);
diarrhea (0.79%); change in taste (0.46%); insomnia
and irritability (0.22%); dizziness (0.77%); headache
(0.42%); allergic reaction (0.18%); changes in the
Central Nervous System – insomnia, agitation, anxiety
–  (0.46%).  In other studies, gatifloxacin was also
safe and showed few adverse effects [14,20-22].
This was a multicenter, prospective, open-label and
noncomparative clinical trial in which gatifloxacin 400
mg was administered once a day for treating respiratory
tract infection. The drug was considered safe and
effective for the treatment of respiratory tract infections.
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